Predictive Value of the Global Limb Anatomic Staging System (GLASS) in Patients With Critical Limb-threatening Ischemia - Trial NCT05999669
Access comprehensive clinical trial information for NCT05999669 through Pure Global AI's free database. This phase not specified trial is sponsored by RenJi Hospital and is currently Not yet recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 2000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
RenJi Hospital
Timeline & Enrollment
N/A
Aug 20, 2023
Dec 31, 2027
Primary Outcome
Rate of freedom from major adverse events (MAEs)
Summary
The Global Vascular Guideline on chronic limb threatening ischemia (CLTI) proposes the Global
 Limb Anatomic Staging System (GLASS), a new angiographic scoring system to quantify the
 anatomic severity of infrainguinal disease in CLTI patients. However, GLASS validation still
 needs to be completed, and the infrapopliteal (IP) target artery pathway (TAP) was easily
 influenced by the procedures. Thus the IP target artery could be selected either as the least
 diseased artery based on angiography or prospectively based on the angiosome concept. So the
 investigators aim to evaluate its correlation with clinical outcomes after revascularization.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05999669
Non-Device Trial